Greater Effectiveness and Enhanced Safety Profiles of Biosimilars Compared to Their Reference Biologics Increasing Their Adoption Worldwid ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

Annual Report/Annual ResultsFormycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CESTThe ...

Sandoz is one of the largest off-patent pharmaceutical manufacturers in the world. It generates roughly 75% of sales from generic drugs with the remainder from biosimilars and has a significant ...

The company emphasized its strategic focus on biosimilars, noting significant investments and a robust pipeline targeting a $200 billion market ... in different regions and markets.

The erythropoietin drugs market was valued at $9,243.12 million in 2020, and is projected to reach $ 14,414.59 million by 2028, registering a CAGR of 5.7% from 2021 to 2028. Rise in number of patients ...

AEON Biopharma, Inc. announced in its press release that it is advancing its biosimilar development program ... has secured exclusive rights in various regions. The press release also highlights ...

The global Central Lab Services Market, valued at US$5.64 billion in 2024, is forecasted to grow at a robust CAGR of 6.5%, ...

The global biotech ingredient market was valued at $51.3 billion in 2020, and is anticipated to generate $75.3 billion by 2028. The market is projected to experience growth at a CAGR of 4.8% from 2021 ...

Hyderabad: Dr Reddy's Labs (DRL) on Wednesday said its subsidiary, Dr Reddy's Labs SA, entered into commercialisation and ...